Adding taxane reduced risk for relapse, death in operable breast cancers

Yee, Doug; Harris, Jason; Shafer, Emily
July 2008
Hem/Onc Today;7/25/2008, Vol. 9 Issue 13, p28
The article discusses research being done on the influence of taxane on the risk for relapse and death in breast cancer patients. It references a study published in the 2008 issue of the "Journal of the National Cancer Institute." The study included 1,246 breast cancer patients who have undergone primary curative surgery with axillary lymph node dissection. Study researchers concluded that a treatment regimen including 5-FU, epirubicin, cyclophosphamide and paclitaxel reduced the risk for relapse and death.


Related Articles

  • Weekly paclitaxel improves survival in breast cancer. Yee, Douglas // Hem/Onc Today;5/25/2008, Vol. 9 Issue 9, p23 

    The article discusses a study of the impact of weekly paclitaxel on the survival of breast cancer patients, which was published in the "New England Journal of Medicine." Results showed a 1.27 odds ration for disease-free survival in patients assigned to weekly paclitaxel. In addition, weekly...

  • Mastectomy vs. Breast-Conserving Therapy for DCIS. Walling, Anne D. // American Family Physician;1/1/2007, Vol. 75 Issue 1, p106 

    The article discusses research being done on breast cancer-specific mortality after invasive local recurrence in patients with ductal carcinoma-in-situ (DCIS) of the breast. It references a study by L. A. Lee et al published in the October 2006 issue of the "American Journal of Surgery."...

  • POST-BREAST CANCER LYMPHEDEMA: 30 MONTHS AFTER DIAGNOSIS. Armer, Jane // Oncology Nursing Forum;Jan2007, Vol. 34 Issue 1, p185 

    Breast cancer survivors are at life-time risk of developing lymph-edema (LE). With the exception of cancer recurrence, LE is the most dreaded cancer treatment sequela. In part because of difficulties and variability in measurement and diagnosis, the reported incidence of LE varies greatly among...

  • Soy Food Intake and Breast Cancer Survival. Xiao Ou Shu; Ying Zheng; Hui Cai; Kai Gu; Zhi Chen; Wei Zheng; Wei Lu // JAMA: Journal of the American Medical Association;12/9/2009, Vol. 302 Issue 22, p2437 

    The article discusses a study which investigated whether soy food intake following breast cancer diagnosis is related to total mortality and cancer recurrence. The study included 5,042 women breast cancer survivors, who were diagnosed between March 2002 and April 2006 in China. It examined the...

  • Phase II study of gemcitabine plus epirubicin plus paclitaxel in metastatic breast cancer patients. Demıray, Mutlu; Evrensel, Türkkan; Saraydaroğlu, Özlem; Ercan, ılker; Gökgöz, şehsuvar; Topal, Uğur; Tolunay, şahsıne; Taşdelen, ısmet; Manavoğlu, Osman; Arslan, Murat; Kanat, Özkan; Kurt, Ender // Turkish Journal of Cancer;Oct2005, Vol. 35 Issue 4, p159 

    Although metastatic breast cancer is essentially incurable, patients achieving a complete response may be good candidates for long term survival. Gemcitabine, epirubicin and paclitaxel have different mechanisms of action. Therefore, we conducted this phase II study to assess efficacy and safety...

  • Axillary recurrence in sentinel lymph node-negative breast cancer patients. P. Poletti; P. Fenaroli; A. Milesi; A. Paludetti; S. Mangiarotti; G. Virotta; E. Candiago; A. Bettini; E. R. Caremoli; R. Labianca; C. Tondini // Annals of Oncology;Nov2008, Vol. 19 Issue 11, p1842 

    Background: Sentinel lymph node biopsy (SLNB) was developed to axillary lymph node dissection (ALND) in the treatment of breast cancer. SLNB is predictive of axillary node status. Major concern is the occurrence of a false-negative SLN. Purpose of this study is to determine the rate of axillary...

  • Radioterapia intraoperatória como protocolo de tratamento do câncer de mama inicial. Bromberg, Silvio Eduardo; de Morais Hanriot, Rodrigo; Pinto Nazário, Afonso Celso // Einstein (16794508);out/dez2013, Vol. 11 Issue 4, p439 

    Objective: To report on preliminary outcomes of single-dose intraoperative radiotherapy for early-stage breast cancer based on local recurrence rates and complications. Methods: Fifty postmenopausal women with ⩽2.5cm breast tumors and clinically normal axillary lymph nodes were submitted to...

  • More cancer survival hope. Rottman, Erin // Shape;Feb2006, Vol. 25 Issue 6, p84 

    The article presents information on a study related to use of the drug Herceptin for the treatment of breast cancer. Two clinical trials partially funded by the Breast Cancer Research Foundation compared treatment options for women with HER-2-positive breast cancer. The study participants either...

  • Predicting distant recurrence in receptor-positive breast cancer patients with limited clinicopathological risk: using the PAM50 Risk of Recurrence score in 1478 postmenopausal patients of the ABCSG-8 trial treated with adjuvant endocrine therapy ... Gnant, M.; Filipits, M.; Greil, R.; Stoeger, H.; Rudas, M.; Bago-Horvath, Z.; Mlineritsch, B.; Kwasny, W.; Knauer, M.; Singer, C.; Jakesz, R.; Dubsky, P.; Fitzal, F.; Bartsch, R.; Steger, G.; Balic, M.; Ressler, S.; Cowens, J. W.; Storhoff, J.; Ferree, S. // Annals of Oncology;Feb2014, Vol. 25 Issue 2, p339 

    We demonstrate that the PAM50 risk of recurrence score provides additional prognostic information for distant recurrences over standard clinical variables in the large clinical trial ABCSG-08. This molecular assay has been optimized to identify intrinsic breast cancer subtypes. This added...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics